---
title: "Ubrelvy (ubrogepant) in acute treatment of migraine: Specific populations questions"
description: "Specific populations questions on Ubrelvy (ubrogepant) in acute treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Can Ubrelvy be used during pregnancy? Can Ubrelvy be used while breastfeeding? Is Ubrelvy approved for children? Has Ubrelvy been studied in adults 65 and older? 3 further questions follow. 7 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ubrelvy (ubrogepant) in acute treatment of migraine: Specific populations questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Ubrelvy](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf)

## Pregnancy and breastfeeding

<a id="ubrelvy-pregnancy"></a>

### Can Ubrelvy be used during pregnancy?

> “Pregnancy Exposure Registry 
> There is a pregnancy exposure registry that monitors outcomes in women who become pregnant 
> while taking UBRELVY. Patients should be encouraged to enroll by calling 1-833-277-0206 or 
> visiting http://empresspregnancyregistry.com. 
> Risk Summary 
> There are no adequate data on the developmental risk associated with the use of UBRELVY in 
> pregnant women. In animal studies, adverse effects on embryofetal development were observed 
> following administration of ubrogepant during pregnancy (increased embryofetal mortality in 
> rabbits) or during pregnancy and lactation (decreased body weight in offspring in rats) at doses 
> greater than those used clinically and which were associated with maternal toxicity (see Data).  
> In the U.S. general population, the estimated background risk of major birth defects and 
> miscarriages in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The 
> estimated rate of major birth defects (2.2% -2.9%) and miscarriage (17%) among deliveries to 
> women with migraine are similar to rates reported in women without migraine.”

Source: [UBRELVY: Prescribing information, page 6, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=6)

<a id="ubrelvy-breastfeeding"></a>

### Can Ubrelvy be used while breastfeeding?

> “Data from a lactation study in twelve healthy adult females indicate that ubrogepant is excreted 
> in breast milk in low amounts. The estimated relative infant dose is approximately 0.15% of the 
> maternal weight-adjusted dose, and the milk-to-plasma ratio is 0.23 (see Data). There are no data 
> on the effects of ubrogepant on the breastfed infant or the effects on milk production. The 
> developmental and health benefits of breastfeeding should be considered along with the mother’s 
> clinical need for UBRELVY and any potential adverse effects on the breastfed infant from 
> UBRELVY or from the underlying maternal condition.”

Source: [UBRELVY: Prescribing information, page 7, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=7)

## Specific populations

<a id="ubrelvy-children"></a>

### Is Ubrelvy approved for children?

> “Safety and effectiveness in pediatric patients have not been established.”

Source: [UBRELVY: Prescribing information, page 7, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=7)

<a id="ubrelvy-older-adults"></a>

### Has Ubrelvy been studied in adults 65 and older?

> “In pharmacokinetic studies, no clinically significant pharmacokinetic differences were observed 
> between elderly and younger subjects. Clinical studies of UBRELVY did not include sufficient 
> numbers of patients aged 65 years and over to determine whether they respond differently from 
> younger patients. In general, dose selection for an elderly patient should be cautious, usually 
> starting at the low end of the dosing range.”

Source: [UBRELVY: Prescribing information, page 7, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=7)

<a id="ubrelvy-liver"></a>

### Does Ubrelvy need a dose adjustment for liver problems?

> “In patients with pre-existing mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or 
> severe hepatic impairment (Child-Pugh Class C), ubrogepant exposure was increased by 7%, 
> 50%, and 115%, respectively. No dose adjustment is recommended for patients with mild or 
> moderate hepatic impairment. Dose adjustment for UBRELVY is recommended for patients with 
> severe hepatic impairment [see Dosage and Administration (2.2)].”

Source: [UBRELVY: Prescribing information, page 7, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=7)

> “Severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (CLcr 15-29 mL/min): recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose<sup>1</sup>”

Source: [UBRELVY: Dosage Instructions + Information, captured 2026-11-14](https://www.ubrelvyhcp.com/dosing#:~:text=Severe%20hepatic%20impairment%20%28Child%2DPugh%20Class,2%20hours%20after%20the%20initial)

<a id="ubrelvy-kidney"></a>

### Does Ubrelvy need a dose adjustment for kidney problems?

> “The renal route of elimination plays a minor role in the clearance of ubrogepant [see Clinical 
> Pharmacology (12.3)]. No dose adjustment is recommended for patients with mild or moderate 
> renal impairment. Dose adjustment is recommended for patients with severe renal impairment 
> (CLcr 15-29 mL/min) [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]. 
> Avoid use of UBRELVY in patients with end-stage renal disease (ESRD) (CLcr <15 mL/min).”

Source: [UBRELVY: Prescribing information, page 8, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=8)

> “Severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (CLcr 15-29 mL/min): recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose<sup>1</sup>”

Source: [UBRELVY: Dosage Instructions + Information, captured 2026-11-14](https://www.ubrelvyhcp.com/dosing#:~:text=Severe%20hepatic%20impairment%20%28Child%2DPugh%20Class,2%20hours%20after%20the%20initial)

> “Avoid use in patients with end-stage renal disease (CLcr <15 mL/min)<sup>1</sup>”

Source: [UBRELVY: Dosage Instructions + Information, captured 2026-11-14](https://www.ubrelvyhcp.com/dosing#:~:text=Avoid%20use%20in%20patients%20with%20end%2Dstage%20renal%20disease%20%28CLcr%20%3C15)

<a id="ubrelvy-overdose"></a>

### What should be done after a Ubrelvy overdose?

> “The elimination half-life of ubrogepant is approximately 5 to 7 hours; therefore, monitoring of 
> patients after overdose with UBRELVY should continue for at least 24 hours, or while 
> symptoms or signs persist.”

Source: [UBRELVY: Prescribing information, page 8, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=8)

## Related pages
- [Medical information: Ubrelvy (ubrogepant): Acute treatment of migraine](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/access-and-coverage)
